Henrik Wulff, the man in charge of product supply at Novo Nordisk just spent $11 billion to try to fill an ocean. Novo has handed Wulff one of the most complex jobs in all of pharmaceuticals. Novo and its competitor Eli Lilly have gone to greater and greater lengths to speed their GLP-1 output, as they battle each other and the increasingly aggressive telehealth industry, which is selling large quantities of legal GLP-1 knockoffs.